Diabetes company TheraSense raises $114 million in IPO (initial public offering)
This article was originally published in Clinica
TheraSense, which has developed a less-painful glucose monitoring system, raised $114 million when it floated last week. The IPO is only the second this quarter, after Israeli company Given Imaging's flotation a week earlier (see Clinica No 978, p 11). TheraSense sold six million shares - a 16% stake - at $19 a share, giving it a market capitalisation of $722 million.